NEW YORK (
TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today.
The Dow falls more than 150 points after a poor read on job creation in March raises fresh doubts about the pace of the economy's recovery.
Here are today's top research calls.
The purchase of Allos Therapeutics cannot make up for the loss of Spectrum's bladder cancer drug. (Stocks include SPPI, ALTH, GILD)
Partial results from a mid-stage study of hepatitis C drugs from Bristol and Gilead was leaked in advance of a key meeting in two weeks.
These stocks, which go ex-dividend Tuesday, are rated buy at TheStreet Ratings.
These stocks received downgrades by TheStreet Ratings last week.
When the next round is required, I expect the Fed will attempt to drive down loan rates with the least amount of balance-sheet expansion as possible.
The media needs to ask where 'cost savings' come from.
These stocks received upgrades to buy at TheStreet Ratings last week.
A bump in March sales shows Volt is outstripping the competition.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV